A global biotech is axing more of its Greater Washington workforce, eliminating nearly 100 positions across multiple waves of ...

A recipient of the 2025 Elite Trial Lawyers Lifetime Achievement Award, Morgan & Morgan's John Yanchunis spoke with the National Law Journal about his storied career, from bringing one of the nation’s ...

An analysis from the Congressional Budget Office warns that cuts to the National Institutes of Health and FDA drug reviews could significantly reduce the number of new medications reaching the U.S.

A Cambridge-based company developing gene therapies for rare diseases is laying off more than a third of its workforce.

The layoffs followed a March announcement by Health Secretary Robert F. Kennedy Jr., who called for a major department overhaul.

The U.S. Congressional Budget Office (CBO) cautioned that President Trumps proposed 2026 federal budgetfeaturing deep cuts to ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

Trump administration officials have defended the mass dismissals, saying they are overdue and necessary to make the department leaner and more efficient. Among the employees laid off are more than 100 ...

According to the company's global financial results for the first quarter, released in May, declines of 19 percent in the ...

Other agencies are moving forward with RIFs and terminations, but official tells federal court some plans have changed.

The investigative unit, which looks into potential safety issues with drugs, vaccines, medical devices, and other products, has had a retention problem for years. Inspectors leave so often that, even ...